Long-term survival of patients (pts) with advanced melanoma treated with ipilimumab with or without dacarbazine

被引：0
|
作者：
Hersh, E.
Weber, J.
Powderly, J.
Pavlik, A.
Nichol, G.
Yellin, M.
Cranmer, L.
Urba, W.
O'Day, S.
机构：
[1] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA
[2] Comprehens Melanoma Res Ctr, Tampa, FL USA
[3] Carolina BioOncol Inst, Hunterville, NC USA
[4] NYU, Med Ctr, New York, NY 10016 USA
[5] Medarex Inc, Bloomsbury, NJ USA
[6] Providence Portland Med Ctr, Portland, OR USA
[7] Angeles Clin, Res Inst, Santa Monica, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9038
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.
    Hodi, F. Stephen
    Sznol, Mario
    Kluger, Harriet M.
    McDermott, David F.
    Carvajal, Richard D.
    Lawrence, Donald P.
    Topalian, Suzanne Louise
    Atkins, Michael B.
    Powderly, John D.
    Sharfman, William Howard
    Puzanov, Igor
    Smith, David C.
    Leming, Philip D.
    Lipson, Evan J.
    Taube, Janis M.
    Anders, Robert
    Horak, Christine E.
    Kollia, Georgia
    Gupta, Ashok Kumar
    Sosman, Jeffrey Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] Long-term outcome of patients with advanced melanoma
    Parolin, V.
    Nortilli, R.
    Strina, C.
    Sabbioni, R.
    Sava, T.
    Cetto, G. L.
    EJC SUPPLEMENTS, 2007, 5 (04): : 400 - 401
  • [33] PROJECTING LONG TERM OVERALL SURVIVAL BENEFIT IN METASTATIC MELANOMA PATIENTS TREATED WITH IPILIMUMAB USING EXTRAPOLATION METHODS
    Kim, Hansoo
    Cook, Greg
    McCloud, Philip
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 : 313 - 313
  • [34] Long-term survival in patients with metastatic melanoma who received ipilimumab in four phase II trials
    Lebbe, Celeste
    Weber, Jeffrey S.
    Maio, Michele
    Neyns, Bart
    Harmankaya, Kaan
    Hamid, Omid
    O'Day, Steven
    Chin, Kevin M.
    McDowell, Diane Opatt
    Cykowski, Lori
    McHenry, Brent
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] EFFICACY AND SAFETY OF PATIENTS WITH ADVANCED MELANOMA TREATED WITH IPILIMUMAB WITH OR WITHOUT THE ADDITION OF PROPHYLACTIC BUDESONIDE
    Ron, I.
    Berman, D.
    Siegel, J.
    Hamid, O.
    Minor, D.
    Amin, A.
    Thompson, J.
    Ridolfi, R.
    Maraveyas, A.
    Weber, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 243 - 243
  • [36] Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma
    D. Lee
    J. Porter
    N. Hertel
    A. J. Hatswell
    A. Briggs
    BioDrugs, 2016, 30 : 307 - 319
  • [37] Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma
    Lee, D.
    Porter, J.
    Hertel, N.
    Hatswell, A. J.
    Briggs, A.
    BIODRUGS, 2016, 30 (04) : 307 - 319
  • [38] Convincing Long-term Data on Nivolumab and Ipilimumab Combination for Patients with Melanoma
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (06) : 2 - 3
  • [39] Prognostic score for patients with advanced melanoma treated with ipilimumab
    Diem, Stefan
    Kasenda, Benjamin
    Martin-Liberal, Juan
    Lee, Alexander
    Chauhan, Dharmisha
    Gore, Martin
    Larkin, James
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (18) : 2785 - 2791
  • [40] Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study
    Queirolo, Paola
    Dozin, Beatrice
    Morabito, Anna
    Banelli, Barbara
    Piccioli, Patrizia
    Fava, Cristiana
    Leo, Claudio
    Carosio, Roberta
    Laurent, Stefania
    Fontana, Vincenzo
    Ferrucci, Pier Francesco
    Martinoli, Chiara
    Cocorocchio, Emilia
    Battaglia, Angelo
    Ascierto, Paolo A.
    Capone, Mariaelena
    Simeone, Ester
    De Galitiis, Federica
    Pagani, Elena
    Cappellini, Gian Carlo Antonini
    Marchetti, Paolo
    Guida, Michele
    Tommasi, Stefania
    Mandala, Mario
    Merelli, Barbara
    Quaglino, Pietro
    Fava, Paolo
    Guidoboni, Massimo
    Romani, Massimo
    Spagnolo, Francesco
    Pistillo, Maria Pia
    FRONTIERS IN IMMUNOLOGY, 2017, 8
12345